We are live on ! Find out more
XFOR icon

X4 Pharmaceuticals
XFOR

93 hedge funds and large institutions have $23.6M invested in X4 Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 28 increasing their positions, 22 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

552% more call options, than puts

Call options by funds: $202K | Put options by funds: $31K

50% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 10

27% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 22

4% more funds holding

Funds holding: 89 → 93 (+4)

0.06% less ownership

Funds ownership: 1.95% → 1.89% (-0.06%)

68% less capital invested

Capital invested by funds: $73.2M → $23.6M (-$49.7M)

Holders
93
Holders Change
+4
Holders Change %
+4.49%
% of All Funds
1.25%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
15
Increased
28
Reduced
22
Closed
10
Calls
$202K
Puts
$31K
Net Calls
+$171K
Net Calls Change
-$245K

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$1.89M
2
KCM
Kingdon Capital Management
New York
+$947K
3
PFCS
Pale Fire Capital SE
Czech Republic
+$291K
4
BlackRock
BlackRock
New York
+$170K
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$56.2K

Top Sellers

Rank Fund Capital Flow
1
Axa
Axa
France
-$1.09M
2
GCP
GSA Capital Partners
United Kingdom
-$934K
3
SSA
Schonfeld Strategic Advisors
New York
-$485K
4
UOC
UBS O'Connor
Illinois
-$465K
5
Group One Trading
Group One Trading
Illinois
-$287K
Name Holding Trade Value Shares
Change 		Change in
Stake
BCLSI
1
Bain Capital Life Sciences Investors
Massachusetts
$4M – – –
NMC
2
NEA Management Company
Maryland
$3.54M – – –
BlackRock
3
BlackRock
New York
$2.7M +$170K +12,322 +3%
Vanguard Group
4
Vanguard Group
Pennsylvania
$1.9M -$61.2K -4,446 -2%
ACA
5
Acorn Capital Advisors
New York
$1.75M – – –
KCM
6
Kingdon Capital Management
New York
$1.65M +$947K +68,766 +42%
O
7
OrbiMed
New York
$1.6M -$164K -11,900 -5%
UBS Group
8
UBS Group
Switzerland
$1.19M +$1.89M +137,137 +446%
Geode Capital Management
9
Geode Capital Management
Massachusetts
$856K +$56.2K +4,082 +4%
State Street
10
State Street
Massachusetts
$722K -$1.02K -74 -0.1%
Ensign Peak Advisors
11
Ensign Peak Advisors
Utah
$529K -$143K -10,360 -12%
PFCS
12
Pale Fire Capital SE
Czech Republic
$481K +$291K +21,113 +45%
Susquehanna International Group
13
Susquehanna International Group
Pennsylvania
$405K -$80.4K -5,841 -9%
Northern Trust
14
Northern Trust
Illinois
$296K -$47.6K -3,457 -8%
CIBC World Market
15
CIBC World Market
Ontario, Canada
$248K +$16.1K +1,167 New
Axa
16
Axa
France
$163K -$1.09M -79,368 -78%
Point72 Asset Management
17
Point72 Asset Management
Connecticut
$154K – – –
Morgan Stanley
18
Morgan Stanley
New York
$135K +$8.95K +650 +4%
Charles Schwab
19
Charles Schwab
California
$114K +$19.9K +1,444 +10%
Bank of New York Mellon
20
Bank of New York Mellon
New York
$81.5K – – –
SSA
21
Schonfeld Strategic Advisors
New York
$79.3K -$485K -35,247 -76%
Goldman Sachs
22
Goldman Sachs
New York
$64.7K -$93.5K -6,792 -43%
Deutsche Bank
23
Deutsche Bank
Germany
$64.2K – – –
Millennium Management
24
Millennium Management
New York
$61.2K – – –
UOC
25
UBS O'Connor
Illinois
$59.6K -$465K -33,725 -80%
1
2 3 4 5

XFOR Hedge Fund Activity: Q1 2025 in Review

93 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in X4 Pharmaceuticals (XFOR) for Q1 2025, worth a combined $23.6M — down 68% from $73.2M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new XFOR positions and 10 closed out — a net gain of 5 holders — while 28 added to existing stakes and 22 trimmed.

The largest buyer was UBS Group, adding an estimated $1.89M. The largest seller was Axa, cutting an estimated $1.09M.

  • 93 institutional investors held X4 Pharmaceuticals (XFOR) as of Q1 2025, up from 89 in Q4 2024.
  • Funds reported $23.6M of X4 Pharmaceuticals stock for Q1 2025, down 68% quarter-over-quarter.
  • 15 funds opened new X4 Pharmaceuticals positions in Q1 2025 and 10 closed out, a net change of +5 holders.
  • The largest X4 Pharmaceuticals buyer in Q1 2025 was UBS Group, an estimated $1.89M added.
  • The largest X4 Pharmaceuticals seller in Q1 2025 was Axa, an estimated $1.09M sold.

Based on aggregated 13F filings for Q1 2025.